Completing data — refresh the page later to see the latest
77337-76-9CC(=O)NCCCS(=O)(=O)OAFCGFAGUEYAMAO-UHFFFAOYSA-NAcamprosate is an organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3. It has a role as a xenobiotic, a neurotransmitter agent and an environmental contaminant. It is a member of acetamides and an organosulfonic acid.
77337-76-9DTXSID3044259CHEMBL1201293CHEBI:51041Pharmaceutical
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Used in Switzerland
Pharmaceuticals
>5mg/mL
1.88e+01 g/L
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl acamprosate calcium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Acamprosate Calcium/
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
Treatment consists of discontinuation of Acamprosate together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may beconsidered, bearing in mind that such medication can produce bronchospasm. (L1712)
Coadministration /with naltrexone/ increases Cmax 33% and AUC 25% of acamprosate...
Acamprosate had no inducing potential on the cytochrome CYP1A2 and 3A4 systems, and in vitro inhibition studies suggest that acamprosate does not inhibit in vivo metabolism mediated by cytochrome CYP1A2, 2C9, 2C19, 2D6, 2E1, or 3A4. The pharmacokinetics of /acamprosate/ were unaffected when coadministered with alcohol, disulfiram or diazepam. Similarly, the pharmacokinetics of ethanol, diazepam and nordiazepam, imipramine and desipramine, naltrexone and 6-beta naltrexol were unaffected following co-administration with /acamprosate/.
N07BB03
N - Nervous system
QN - Nervous system
Acamprosate acts on the CNS, aiding in the restoration of normal glutaminergic neuron activity. Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent individuals, likely through effects on NMDA receptors and calcium channels. It is a safe and well-tolerated drug for patients with alcohol dependency and improves the likelihood of alcohol abstinence.
The mechanism of action of acamprosate for the maintenance of alcohol abstinence has not been established. Chronic alcohol exposure is believed to modify the balance between neuronal excitation and inhibition. Results of studies in animals suggest acamprosate may interact with glutamate and GABA neurotransmitter systems in the CNS, supporting the hypothesis that acamprosate restores the balance between neuronal excitation and inhibition. Evidence shows that acamprosate directly binds and inhibits GABA B receptors and indirectly affects GABA A receptors.
... Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. In vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.
In pharmacokinetic studies, enteric-coated acamprosate tablets demonstrate a terminal elimination half-life 10-fold higher than reported 3 hour half-life after intravenous infusion of acamprosate. After two oral doses of acamprosate 333mg, the terminal half-life ranges between 20 - 33 hours.
Acamprosate therapy has not been associated with serum enzyme elevations over and above rates that occur with placebo therapy. Despite widescale use in alcohol treatment programs, there have yet to be published reports of clinically apparent acute liver injury attributed to acamprosate therapy.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that acamprosate is expected to have very high mobility in soil(SRC). The estimated pKa of acamprosate is 0.27 (sulfonic acid)(3), indicating that this compound will exist primarily as an anion in the environment. Volatilization of acamprosate from moist soil surfaces is not expected to be an important fate process(SRC) because anions do not volatilize. Acamprosate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.8X10-8 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data for acamprosate were not available(SRC, 2005).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that acamprosate is not expected to adsorb to suspended solids and sediment(SRC). The pKa of acamprosate is 0.27 (sulfonic acid)(3), indicating that this compound will exist primarily as an anion in the environment. Volatilization from water surfaces is not expected(SRC) since anions do not volatilize. According to a classification scheme(4), an estimated BCF of 3(SRC), from an estimated log Kow of -2.9(5) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data for acamprosate were not available(SRC, 2005).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), acamprosate, which has an estimated vapor pressure of 1.8X10-8 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase acamprosate may be removed from the air by wet or dry deposition(SRC). Acamprosate does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).
The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. <i>in vitro</i> and <i>in vivo</i> studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. It seems to inhibit NMDA receptors while activating GABA receptors.
Using a structure estimation method based on molecular connectivity indices(1), the Koc of acamprosate can be estimated to be 10(SRC). According to a classification scheme(2), this estimated Koc value suggests that acamprosate is expected to have very high mobility in soil. The estimated pKa of acamprosate is 0.27 (sulfonic acid)(3), indicating that this compound will exist primarily as an anion in the environment and anions generally do not adsorb to soil as strongly as their neutral counterparts(4).
/HUMAN EXPOSURE STUDIES/ adverse events of a suicidal nature (suicidal ideation, suicide attempts, completed suicides) were infrequent overall, but were more common in /acamprosate/-treated patients than in patients treated with placebo (1.4% vs. 0.5% in studies of 6 months or less; 2.4% vs. 0.8% in year-long studies). Completed suicides occurred in 3 of 2272 (0.13%) patients in the pooled acamprosate group from all controlled studies and 2 of 1962 patients (0.10%) in the placebo group. Adverse events coded as "depression" were reported at similar rates in /acamprosate/-treated and placebo-treated patients. Although many of these events occurred in the context of alcohol relapse, no consistent pattern of relationship between the clinical course of recovery from alcoholism and the emergence of suicidality was identified.
/HUMAN EXPOSURE STUDIES/ In all reported cases of acute overdosage with /acamprosate/ (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with /acamprosate/ was diarrhea. Hypercalcemia has not been reported in cases of acute overdose. A risk of hypercalcemia should be considered in chronic overdosage only. Treatment of overdose should be symptomatic and supportive.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl acamprosate calcium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Acamprosate Calcium/
Terminal: 20 to 33 hours following oral dosing of 2 x 333 mg.
Acamprosate is not metabolized.
Acamprosate does not undergo metabolism.
Acamprosate does not undergo metabolism. Route of Elimination: Following oral administration of CAMPRAL™, the major route of excretion is via the kidneys as acamprosate. Half Life: 20 - 33 hours
Acamprosate is absorbed in the gastrointestinal tract. The absolute bioavailability of acamprosate after oral administration is about 11%. The effect of food absorption is clinically insignificant and no adjustment of the dose is necessary with regard to meals. After repeated oral doses of 666 mg 3 times a day, steady-state concentrations are achieved within 5 to 7 days, with plasma concentration ranging between 370 to 650 micrograms/L.
Half of acamprosate excretion occurs as unchanged acetyl-homotaurine in urine, and the other half possibly by biliary excretion. The kidneys are primarily responsible for the elimination of acamprosate.
At steady state concentrations, the distribution of acamprosate is about 20L. Following intravenous administration, the volume of distribution is about 72-109 L (an estimated 1 L/kg).
Severe renal insufficiency decreases the elimination of acamprosate, and is a contraindication. An acamprosate dose of 333mg, three times daily, is recommended for moderate renal impairment (creatinine clearance of 30-50 mL/min).
Protein binding: Negligible.
Volume of distribution (VolD): 72 to 109 liters (approximately 1 L/kg) following intravenous administration.
Alcohol Deterrents
Use (kg) in Switzerland (2009): >250
For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
UsesTreatment of alcohol dependency.
DefinitionChEBI: An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.